St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
The variant especially increases stroke risk among childhood cancer survivors who received an intermediate dose of radiation.
Starting with samples from an 11-year-old boy with spitzoid melanoma, researchers identified recurrent MAP3K8 fusions that may respond to MEK inhibitors.
A common variant polygenic risk score, rare cancer risk gene mutations, and prior treatments each provide clues to breast cancer risk in childhood cancer survivors.
A $5 million NIH grant will fund CPIC's ongoing work to develop PGx guidelines and an API for incorporating them into EHRs and clinical decision support systems.
The RNA-seq data, for nearly 40,000 cells from the developing mouse brain, can be explored through an interactive online interface called Cell Seek.
Researchers found that the diverse features in mixed phenotype acute leukemia may stem from early blood progenitor mutations.
A group led by St. Jude Children's Research Hospital integrated transcriptomic, epigenomic, proteomic, and phoshoproteomic data.
An international team found that survival estimates differed significantly between patients with germline mutations in different medulloblastoma predisposition genes.
St. Jude researchers found germline mutations in the transcription factor gene IKZF1 in 0.9 percent of presumed sporadic pediatric acute lymphoblastic leukemia cases.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.